)
Dinesh Chandra
Associate Director, Lung Cancer Initiative (LCI),
Johnson & Johnson
Dinesh Chandra serves as the Associate Director at Interventional Oncology (INTO), within the esteemed Johnson & Johnson (J&J) organization. In this role, he spearheads various Interventional Oncology discovery preclinical drug development programs dedicated to treating solid tumors locally. Dinesh holds a Ph.D. in Immunology from the Sanjay Gandhi Post Graduate Institute of Medical Sciences in Lucknow, India. Commencing his oncology journey as a Senior Postdoc Fellow at Albert Einstein College of Medicine (AECOM), Dinesh delved into groundbreaking research involving Listeria-based cancer vaccines, STING agonists, and the development of combination therapies incorporating cryoablation for cancer treatment. His initial foray into the industry at Eisai saw him assume the pivotal position of Translational Biomedicine and Biomarker Lead for Immuo-oncology discovery programs. Prior to his current role at J&J, Dinesh contributed significantly to diverse preclinical Oncology programs at AstraZeneca. His wealth of experience spans the intricacies of solid tumor targeting, immunological research, and the translation of scientific advancements into innovative therapeutic solutions for cancer treatment.